688238 Obio Technology
- 4.72
- +0.15+3.28%
Obio Technology News
Heyuan Biotech (688238): Revenue is growing steadily, and new orders have maintained a month-on-month growth trend
Heyuan Biotech (688238): CDMO business consolidates leading position, various businesses maintain steady development
Heyuan Biotech (688238): The 23-year performance is under pressure, and the performance of the new capacity investment industry in Lingang is expected to improve sequentially
Heyuan Biotech (688238) 2023 Annual Report 2024 Quarterly Report Comment: CGTCRO is growing steadily, new orders from CDMO are picking up and improving
Heyuan Biotech (688238): CDMO gradually recovers and expects further release of production capacity in Lingang
Heyuan Biotech (688238): CDMO business is under pressure and capacity utilization is expected to increase
Heyuan Biotech (688238): Steady growth in CRO business and release of new production capacity is expected to drive CDMO business recovery
Heyuan Biotech (688238): Lingang GMP base is gradually put into production and new orders are expected to continue to improve
Heyuan Biotech (688238): The release of production capacity at the Lingang base is expected to recover profit margins
Heyuan Biotech (688238): Short-term performance pressure and commissioning of the Lingang base will drive steady growth in performance
Heyuan Biotech (688238): One-stop service, strong competitiveness, GMP base production capacity is expected to be released
Heyuan Biotech (688238) 2023H1 review: The CDMO business continues to be under pressure, waiting for the industry to recover and new production capacity to be released
Heyuan Biotech (688238): Short-term fluctuations in CDMO business, new production capacity supports the company's future development
Heyuan Biotech (688238): Q2 month-on-month improvements continue to strengthen platform construction
Heyuan Biotech (688238): CDMO business is expected to resume growth after short-term pressure production capacity is released
Heyuan Biotech (688238): Growth slows, performance is under short-term pressure, capacity release supports long-term development
Heyuan Biotech (688238): The pandemic & short-term demand disturbances are expected to deliver results
Heyuan Biotech (688238): Short-term demand declines and performance are under pressure, waiting for the release of the company's production capacity in Lingang
Heyuan Biotech (688238): 22Q4 results were disrupted by factors such as the deregulation of controls due to the epidemic and other factors. It is expected that future performance will resume rapid growth
Heyuan Biotech (688238): Performance is in line with expectations and optimistic about future development space
No Data